Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
basiliximab + cyclosporine + everolimus
- Development stage
- Phase 3
- Lead developer
- Centre Hospitalier Universitaire de Brest
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
"Anti R-IL2 + Cyclosporine then Everolimus" is a combination immunosuppressive regimen used in the 'Switch' arm of a Phase 3 clinical trial (NCT01028092) sponsored by University Hospital, Brest. The regimen is designed for elderly renal transplant recipients receiving grafts from elderly donors (the 'old-for-old' strategy). It consists of induction therapy with the anti-IL-2 receptor monoclonal antibody basiliximab (Simulect), followed by maintenance therapy with mycophenolate mofetil (Cellcept), corticosteroids, and cyclosporine A (Neoral). The protocol involves an early switch from the calcineurin inhibitor cyclosporine to the mTOR inhibitor everolimus (Certican) to minimize CNI-related nephrotoxicity and improve long-term graft function.
- Brand names
- CerticanCellcept
- Other names
- anti r-il2 + cyclosporine then everolimusEverolimus-based CNI minimization strategySwitch arm of NCT01028092
02
Targets
CN (Calcineurin)PPIA (Peptidyl-prolyl cis-trans isomerase A)FKBP1AIL2RA (Interleukin-2 receptor alpha subunit)Mechanistic target of rapamycin complex 1GR (Glucocorticoid receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on basiliximab + cyclosporine + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on basiliximab + cyclosporine + everolimus.